NeoALTTO Scoring Guidelines and Approval Criteria

Residual Biological Samples

Project Title:

Principle Investigator:

Assessor:

Do you recommend that this proposal is taken forward for further review / development into a translational project?

Yes / No

SCIENTIFIC SCORING CRITERIA:	**Score (1-5)[1]**
1. Potential clinical impact of the proposed project:	
2. Robustness and adequacy of the tissue analysis technology that is proposed:	
3. Novelty, Innovation and Merit	
4. Statistical design and overall strategy of the study:	
5. Appropriate use of tissue:	
6. Priority	
SCIENTIFIC SCORE	
Additional 2 points ONLY if INTERNAL PROPOSAL	
TOTAL SCORE	

[1] Score 1= least quality, 5= highest quality

OBLIGATORY CRITERIA:

Adequate potential funding to carry out the research:	**YES / NO**
Local EC/IRB approval:	**YES[2]/ NO**
ALTTO trials' patient informed consent form covers the scope of the research project:	**YES / NO[3]**

Approval Criteria:
TRANSALTTO Committee approval will be proposed if all obligatory criteria are met and the average scientific score is ≥ 24. Recommendation to the ALTTO/NeoALLTTO studies' SC will be based on initial review and scoring of the TRANSALTTO committee designated members. The SC will endorse (or not) the recommended proposals.

[2] Conditional approval of a project is possible with pending EC/IRB decision but bio specimens will not be released until full EC/IRB approval (if applicable).
[3] If existing informed consent form does not fully cover the proposed research, the research could be modified accordingly. If the proposed research can't comply with the informed consent signed by the patient, the proposal will be rejected.

Please report any comments concerning the proposal under the appropriate heading below:

1. **Potential clinical impact of the proposed project:**
2. **Robustness and adequacy of the tissue analysis technology that is proposed:**
3. **Novelty, Innovation and Merit:**
4. **Statistical design and overall strategy of the study:**
5. **Appropriate use of tissue:**
6. **Priority:**
7. **Any other comments**: